Temixys (Oral)
Generic name:lamivudine and tenofovir (oral route) [ la-MIV-ue-deen, ten-OF-oh-vir-dye-soe-PROX-il-FUE-ma-rate ]
Drug class:Antiviral combinations
Medically reviewed by Drugs.com. Last updated on May 12, 2022.
Warning: Post Treatment Acute Exacerbations of Hepatitis BSevere acute exacerbations of hepatitis B have been reported in patients who are co-infected with hepatitis B virus (HBV) and human immunodeficiency virus (HIV-1) and have discontinued lamivudine or tenofovir disoproxil fumarate. Monitor hepatic function closely with both clinical and laboratory follow-up for at least several months in patients who discontinue lamivudine/tenofovir disoproxil fumarate and are co-infected with HIV-1 and HBV . If appropriate, initiate anti-hepatitis B treatment .
Commonly used brand name(s)
In the U.S.
- Cimduo
- Temixys
Available Dosage Forms:
- Tablet
Therapeutic Class: Antiretroviral Agent
Pharmacologic Class: Nucleoside Reverse Transcriptase Inhibitor
Uses for Temixys
Lamivudine and tenofovir combination is used together with other antiviral medicines to treat human immunodeficiency virus (HIV) infection. HIV is the virus that causes acquired immune deficiency syndrome (AIDS).
This medicine does not cure or prevent HIV or AIDS. It helps keep HIV from reproducing and appears to slow down the destruction of the immune system. This may help delay the development of problems that usually result from AIDS or HIV disease. It will not keep you from spreading HIV to other people. People who receive this medicine may continue to have some of the problems usually related to AIDS or HIV disease.
This medicine is available only with your doctor's prescription.
Before using Temixys
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of lamivudine and tenofovir combination in children weighing 35 kilograms (kg) or more. Safety and efficacy have been established.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of lamivudine and tenofovir combination in the elderly. However, elderly patients are more likely to have age-related kidney, liver, or heart problems, which may require caution in patients receiving lamivudine and tenofovir combination.
Breastfeeding
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the..
